• LG 101506: Strategic RXR Modulation in Cancer Immunity Resea

  2026-06-25

  Explore how LG 101506, a synthetic RXR modulator, empowers translational researchers to decode the interplay between nuclear receptor signaling and immune checkpoint regulation. This article delivers mechanistic insights, practical protocol guidance, and strategic recommendations for advancing immunometabolic research and precision oncology.

• Aurora A Kinase Regulates Trained Immunity via SAM Metabolis

  2026-06-24

  Li et al. (2025) uncover a novel role for Aurora kinase A in sustaining trained immunity by preserving endogenous S-adenosylmethionine (SAM) levels, linking cell cycle kinase activity to metabolic-epigenetic regulation in inflammatory gene priming. This mechanistic insight has broad implications for cancer biology and immunometabolic research, and informs future experimental approaches targeting Aurora A.

• Scenario-Driven Reliability with T7 RNA Polymerase (SKU K108

  2026-06-23

  This article provides a scenario-based, evidence-driven guide to improving RNA synthesis workflows using T7 RNA Polymerase (SKU K1083), a recombinant enzyme expressed in E. coli. Drawing on real laboratory challenges, peer-reviewed data, and protocol optimization strategies, it demonstrates how K1083 delivers high-yield, template-specific RNA for applications in RNA vaccine production, antisense RNA, and RNAi research.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-23

  Schwartz’s dissertation provides a nuanced analysis of how in vitro assays measure cancer drug responses, distinguishing between proliferative arrest and cell death. By clarifying these metrics and their interplay, the work enhances the interpretation of cytotoxicity data and informs more precise preclinical drug evaluation strategies.

• JEV-Induced Lysosomal Dysfunction via LAMP1/2 Downregulation

  2026-06-22

  This study uncovers a novel mechanism by which Japanese Encephalitis Virus (JEV) impairs lysosomal function through the downregulation of LAMP1 and LAMP2, mediated by its NS4B protein. The findings provide mechanistic insight into autophagy-lysosome pathway disruption during viral infection, with implications for antiviral and autophagy research.

• Ibrexafungerp’s Sustained Antifungal Activity at Vaginal pH

  2026-06-22

  The highlighted study demonstrates that ibrexafungerp (MK 3118) maintains potent in vitro antifungal activity against both fluconazole-susceptible and -resistant vaginal Candida isolates, even under acidic pH conditions characteristic of vulvovaginal candidiasis. These findings support the therapeutic value of ibrexafungerp for treating resistant Candida infections in environments where azole agents are less effective.

• Crystal Violet Staining: Rethinking Nuclear Dye Utility in T

  2026-06-21

  This thought-leadership article explores how Crystal Violet Staining Solution, a classic nuclear staining dye, is evolving from a staple in cell-based assays to a strategic tool for translational researchers. By connecting mechanistic insights, experimental evidence, and workflow optimization, we guide innovators in leveraging this dye for rigorous, reproducible data and competitive laboratory advantage. Drawing on recent surgical pathology findings, we position APExBIO’s Crystal Violet Staining Solution as a platform for robust nuclear visualization in assays ranging from colony formation to migration, with practical protocol parameters and evidence-based strategic recommendations.

• Perphenazine (SKU B6157): Optimizing Cell Viability and Host

  2026-06-20

  This article addresses common laboratory challenges in cell viability and immunomodulation assays, detailing how Perphenazine (SKU B6157) provides robust, reproducible solutions for dopamine D2 receptor antagonist research. Scenario-driven Q&A blocks guide researchers in optimizing protocols, interpreting data, and selecting reliable vendors, with direct links to APExBIO’s Perphenazine product and the latest evidence.

• Lanabecestat (AZD3293): Optimizing BACE1 Inhibition in Alzhe

  2026-06-19

  Lanabecestat (AZD3293) offers precise, synaptic-sparing BACE1 inhibition for Alzheimer's disease research, enabling targeted amyloid-beta reduction with minimal impact on neuronal function. Discover practical workflows, advanced assay strategies, and troubleshooting tips to maximize experimental success with this potent, blood-brain barrier-penetrant compound.

• Smoothened’s Role in Honeybee Olfaction: Expression and Agon

  2026-06-19

  Guo et al. (2024) provide the first detailed molecular and functional analysis of the Smoothened (Smo) protein in Apis mellifera, establishing its crucial role in modulating olfactory receptor expression and sensory behavior. Their findings not only clarify Smo’s localization and regulatory effects in insect olfaction but also open avenues for using Smoothened agonists to dissect conserved Hedgehog signaling beyond traditional contexts.

• LG 101506 (RXR Modulator): Precision Tools for RXR Signaling

  2026-06-18

  Explore LG 101506, a synthetic RXR modulator, as a precision tool for advanced RXR signaling pathway research in immuno-oncology. Uncover novel assay strategies, practical protocol insights, and expert guidance on leveraging RXR modulation for cancer and metabolism studies.

• Simvastatin (Zocor): Applied Workflows in Lipid and Cancer R

  2026-06-18

  Simvastatin (Zocor) is a versatile tool for dissecting cholesterol metabolism and apoptosis induction in hepatic cancer models. This guide delivers actionable protocol enhancements, troubleshooting strategies, and translational insights for maximizing the impact of Simvastatin in cell-based and animal studies.

• 5X Protein Loading Buffer (Reducing): SDS-PAGE Protocol Deta

  2026-06-17

  5X Protein Loading Buffer (Reducing) addresses the need for complete protein denaturation and disulfide bond reduction prior to SDS-PAGE, allowing accurate separation by molecular weight. It is specifically designed for workflows requiring reducing conditions and is not appropriate when preservation of native or non-reducing protein structures is necessary.

• Forsythoside E: PKM2 Inhibitor for Sepsis-Induced Liver Inju

  2026-06-17

  Forsythoside E is a next-generation PKM2 inhibitor enabling precise metabolic reprogramming in macrophage-driven sepsis models. Its robust, validated workflow parameters and unique mechanism make it a standout tool for liver injury research and immunometabolic studies.

• Lanabecestat (AZD3293): Applied Workflows for Alzheimer’s Re

  2026-06-16

  Lanabecestat (AZD3293) stands out for its nanomolar BACE1 inhibition and proven synaptic safety at moderate doses, empowering Alzheimer’s researchers to tune amyloid-beta reduction with precision. Explore stepwise protocols, troubleshooting, and practical insights that bridge recent evidence with translational assay optimization.

483 records 9/33 page Previous Next First page 上5页 678910 下5页 Last page